Clay B. Siegall is a renowned science expert who has spent most of his career conducting research on cancer and genetics. He holds a Ph.D. in Genetic from the George Washington University. Siegall has had a successful career as a researcher, and he is the co-founder of Seattle Genetics. He currently acts as the president of the corporation. Seattle Genetics was established in 1998, and its primary goal is to conduct research, develop new drugs, and also make unique scientific discoveries. Clay has been striving to ensure that the company develops the best medications that can be used in curing cancer. He has been guiding the business in the development and manufacture of antibody-drug conjugates (ADCs). Seattle Genetics created its first FDA-licensed drug in 2011, and it was known as ADCETRIS®. The company has currently partnered with Takeda Pharmaceutical Company to distribute the drugs in more than 65 countries where it is accepted. Clay has been leading the researchers at his firm in developing better ADCs.
Dr. Seigall has led Seattle Genetics in manufacturing and supplying its drugs across the globe by ensuring that it acquires all the strategic licenses that are required. The major drugs that are sold the firm include AbbVie, Genentech, GlaxoSmithKline, and Pfizer. The company has managed to generate profits of more than $350 million from the supply of its ADCs. Its top notch technology has been used in the manufacture of 20 different types of ADCs. The company has been partnering with various pharmaceutical corporations to assist in the external production of its drugs. The financing strategies that have been established by Clay Siegall have enabled Seattle Genetics to secure over $1.2 billion from investors.
Before the establishment of the Seattle Genetics, Clay served at various leading pharmaceutical firms. His first job was at the National Cancer Institute, and after a few years, he got a better position at Bristol-Myers Squibb Pharmaceutical Research Institute. He has also served on the boards of Ultragenyx Pharmaceutical, Washington Roundtable, and BioPharmaceutica. Siegall is passionate about his research work and holds over 15 patents for his innovations. He also owns over 70 publications that are used for academic and professional reference.